Human Inducible Pluripotent Stem Cells and Autism Spectrum Disorder: Emerging Technologies.
Lab-grown neurons from kids with ASD are ready for fast drug screening, moving autism science from mice to human cells.
01Research in Context
What this study did
Carter et al. (2016) wrote a narrative review. They looked at how lab-grown human neurons, made from a patient’s own skin cells, can model autism.
The paper explains the jump from mouse brains to living human cells. It maps how these “iPSC” cultures can speed drug screening.
What they found
The review argues that iPSC neurons give a clearer picture of autism biology than animal models. Labs can now test drugs on a child’s own cells before giving the drug to the child.
How this fits with other research
Torigata et al. (2026) go one step further. Their 2026 meta-analysis pools single-cell data from stem-cell neurons with 1q21.1 deletions. They flag BPTF chromatin remodeling as a drug target, showing the next use of the very models W et al. promoted.
Gibson et al. (2021) take the opposite road. Their scoping review covers 388 play-based assessments for kids with ASD. It keeps the focus on behavior, not cells. The two reviews sit at opposite ends of the bench-to-clinic bridge.
Silleresi et al. (2020) split verbal children into five language-cognitive profiles. Their work reminds us that autism is heterogeneous, so any iPSC model must match the right profile to be useful.
Why it matters
You now have two assessment worlds: high-tech dishes and low-tech playrooms. When a family asks why a drug trial starts, you can explain that scientists already tested the compound on neurons carrying the child’s exact DNA. Keep an eye on iPSC papers; they will tell you which molecular pathways, like BPTF, may soon become pill targets.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a note to your evidence folder: iPSC models exist; check future studies for drug findings that match your clients’ genetic reports.
02At a glance
03Original abstract
Autism Spectrum Disorder (ASD) is a behaviorally defined neurodevelopmental condition. Symptoms of ASD cover the spectrum from mild qualitative differences in social interaction to severe communication and social and behavioral challenges that require lifelong support. Attempts at understanding the pathophysiology of ASD have been hampered by a multifactorial etiology that stretches the limits of current behavioral and cell based models. Recent progress has implicated numerous autism-risk genes but efforts to gain a better understanding of the underlying biological mechanisms have seen slow progress. This is in part due to lack of appropriate models for complete molecular and pharmacological studies. The advent of induced pluripotent stem cells (iPSC) has reinvigorated efforts to establish more complete model systems that more reliably identify molecular pathways and predict effective drug targets and candidates in ASD. iPSCs are particularly appealing because they can be derived from human patients and controls for research purposes and provide a technology for the development of a personalized treatment regimen for ASD patients. The pluripotency of iPSCs allow them to be reprogrammed into a number of CNS cell types and phenotypically screened across many patients. This quality is already being exploited in protocols to generate 2-dimensional (2-D) and three-dimensional (3-D) models of neurons and developing brain structures. iPSC models make powerful platforms that can be interrogated using electrophysiology, gene expression studies, and other cell-based quantitative assays. iPSC technology has limitations but when combined with other model systems has great potential for helping define the underlying pathophysiology of ASD. Autism Res 2016, 9: 513-535. © 2015 International Society for Autism Research, Wiley Periodicals, Inc.
Autism research : official journal of the International Society for Autism Research, 2016 · doi:10.1002/aur.1570